Abstract
Tumor lysis syndrome refers to the metabolic disturbances (hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia) associated with lymphoproliferative malignancies which occur secondary to cell lysis. In some patients, tumor lysis results in acute renal failure. The nature and severity of the metabolic alterations are variable and may be influenced by the timing and intensity of chemotherapy, the magnitude of cell lysis, and the general condition of the patients with respect to hydration and glomerular filtration rate. Not only do hyperuricemia and hyperphosphatemia result from tumor lysis syndrome, they also contribute to oliguric acute renal failure in patients with tumor lysis. The pathogenesis of tumor lysis syndrome and current therapeutic strategies are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 68:486–491
Stapleton FB, Strother DR, Roy S III, Wyatt RJ, McKay CP, Murphy SB (1988) Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 82:863–869
Kjellstrand CM, Campbell DC, von Hartitzsch B, Buselmeier TJ (1974) Hyperuricemic acute renal failure Arch Intern Med 133:349–359
Jones DP, Stapleton FB, Kalwinsky D, McKay CP, Kellie SJ, Pui C-H (1990) Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med Pediatr Oncol 18:283–286
Allon M, Llach F (1988) Hyperphosphatemia, hypocalcemia, and renal failure in a patient with acute leukemia. Am J Kidney Dis 11:442–445
Monballyu J, Zachee P, Verberckmoes R, Boogaerts MA (1984) Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 22:7–50
Kaplan BS, Hebert D, Morrell R-E (1981) Acute renal failure induced by hyperphosphatemia in acute lymphoblastic leukemia. Can Med Assoc J 124:429–431
Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, Little AS (1970) Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 283:354–357
Andreoli SP, Clark JH, McGuine, WA, Bergstein JM (1986) Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 109:292–298
Baldree LA, Stapleton FB (1990) Uric acid metabolism in children. Pediatr Clin North Am 37:391–418
Rieselbach RE, Bentzel CJ, Cotlove E, Frei E, Freireich EJ (1964) Uric acid excretion and renal function in the acute hyperuricemia of leukemia: pathogenesis and therapy of uric acid nephropathy. Am J Med 37:872–884
Mir MA (1977) Renal excretion of uric acid and its relation to relapse and remission in acute myeloid leukemia. Nephon 19:69–80
Emmerson Bryan T (1988) Hyperuricemia, gout, and the kidney. In: Schrier RW, Gottschalk CW (eds) Diseases of the kidney. Little Brown, Boston, pp 2481–2510
Kanfer A, Richet G, Roland J, Chatelet F (1979) Extreme hyperphosphatemia causing acute anuric nephrocalcinosis in lymphosarcoma. BMJ 1:1920–1921
Conger JD, Falk SA (1977) Intrarenal dynamics in the pathogenesis and prevention of acute nephropathy. J Clin Invest 59:786–793
Zusman J, Brown DM, Nesbit ME (1973) Hyperphosphatemia, hyperphosphaturia, and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 289:1335–1340
Ettinger DS, Harker WG, Gerry HW, Sanders RD, Saral R (1978) Hyperphosphatemia, hypocalcemia, and transient renal failure. JAMA 239:2472–2474
Cadman EC, Lundberg WB, Bertino JR (1977) Hyperphosphatemia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 62:283–288
Holland P, Holland NH (1968) Prevention and management of acute hyperuricemia in childhood leukemia. J Pediatr 72:358–366
Masera G, Jankovic M, Zurlo MG, Locasciulli A, Rossi MR, Uderzo C, Recchia M (1982) Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 100: 152–155
Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Hershfield MS (1988) Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 109:114–117
Davis S, Park YK, Abuchowski A, Davis FF (1981) Hypouricemic effect of polyethylene glycol modified urate oxidase. Lancet II: 281–283
Steinberg SM, Galen MA, Lazarus JM, Lowrie EG, Hampers CL, Jaffe N, (1975) Hemodialysis for acute anuric acid nephropathy. Am J Dis Child 129:956–958
Deger GE, Wagoner RD (1972) Peritoneal dialysis in acute uric acid nephropathy. Mayo Clin Proc 47:189–192
Bishof NA, Welch TR, Strife CF, Ryckman FC (1990) continuous hemofiltration in children. Pediatrics 85:819–823
Heney D, Essex-Cater A, Brocklebank JT, Bailey CC, Lewis IJ (1990) Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol 4:245–247
Sakarcan A, Quigley R (1994) Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 8:351–353
Saccente SL, Kohaut EC, Berkow RL (1993) Prevention of tumor lysis syndrome (TLS) using continuous veno-venous hemofiltration. J Clin Oncol 11:252a
Maher JF (1989) Pharmacologic consideration for renal failure and dialysis. In: Maher JF (ed) Replacement of renal function by dialysis, 3rd edn. Kluwer, Dordrecht, pp 1018–1076
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, D.P., Mahmoud, H. & Chesney, R.W. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 9, 206–212 (1995). https://doi.org/10.1007/BF00860751
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00860751